Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss biotech company Novimmune and South Korea based LegoChem Biosciences (LCB) have entered into a research collaboration to evaluate an antibody drug conjugate candidate.
Subscribe to our email newsletter
LCB has been successfully developing global partnerships through the potential of its proprietary ADC platform technology.
In 2015, LCB out-licensed an anti-Her2-ADC molecule to Fosun Pharma and in January 2017, signed a research licensing deal with Takeda, to evaluate next-generation ADC candidates.
Novimmune Chairman and CEO Eduard Holdener said: “Our antibody expertise married with LCB’s proprietary ADC technology, supports our quest to provide better options to cancer patients.”
ADCs are molecules composed of a tumor specific monoclonal antibody linked to a cytotoxic agent. Unlike chemotherapy, they are intended to target only cancer cells and spare healthy cells.
Novimmune brings expertise in the field of targeted therapies with their anti-CD47/anti-CD19 and anti-CD47/anti-mesothelin bispecific antibodies that selectively bind to hematological and solid tumors, respectively.